The Winship Cancer Institute (WCI) of Emory University is the first and only cancer center in Georgia with designation from the National Cancer Institute (NCI). For more than 70 years, the medical experts of this Atlanta-based institution have used Emory’s vast resources in thoracic surgery, medical oncology, radiation oncology, surgical oncology and pulmonology to work toward the prevention, treatment and control of cancer. Placing strong emphasis on a multidisciplinary approach to patient care, WCI offers advanced treatments and early clinical trials of promising new therapies for patients throughout Georgia and the Southeast.
Not only does WCI benefit from the support of the NCI and Emory University, but it also receives more than $28 million in funding from nine esteemed organizations, including:
Initiated more than 20 years ago, WCI’s partnership with the Georgia Institute of Technology has developed into one of the leading bioengineering and biomedical research programs in the United States. Cross-cutting initiatives like this pool the talents and resources of Winship researchers and leaders of innovative technology to improve patient care and save lives. Altogether, these partnerships help facilitate compassionate clinical care to more than 5,000 new cancer patients per year.
Committed to providing the best treatment for all types of cancer, the cancer care team at WCI accelerates the achievement of this goal by recruiting the world’s most prominent cancer researchers and physicians. The Winship Cancer Institute also boasts a leading team of oncologists and thoracic surgeons devoted to lung cancer and mesothelioma.
Among this team is Daniel Miller, M.D., assistant professor of Surgery and the surgical director of the Thoracic Oncology Program at WCI. Considered one of the world’s leading authorities on lung cancer and mesothelioma, Miller’s research focuses on bronchoscopy, dysphagia, esophageal cancer, lobectomy, lung disease and thoracic surgery. He strongly supports trimodality therapy (surgery combined with chemotherapy and radiation) to offer the best chance of a cure for patients suffering from malignant pleural mesothelioma.
Dong M. Shin, M.D., shares Miller’s special interest in treating mesothelioma. As the director of the Clinical and Translational Cancer Prevention Program, Shin works within his specialty to develop biomarkers, or biological substances that can be measured to indicate an increased risk of disease. Shin’s research has also found notable positive results in the treatment of pleural mesothelioma with a combination of chemotherapy and vitamin supplementation.
Yet another prominent researcher on Winship’s team is Suresh Ramalingam, M.D., director of the Division of Medical Oncology. He is also the leader of WCI’s Discovery and Developmental Therapeutics Program and the chair of the Thoracic Malignancies Committee for the Eastern Cooperative Oncology Group, one of the largest clinical cancer research organizations in the United States. Ramalingam has a reputation of excellence in translational research and is a leading national expert on lung cancer and mesothelioma.
Research groups at the Winship Cancer Institute span multiple disciplines and study areas including cancer prevention, oncology, cancer genetics and more. There are four full research programs: Cancer Cell Biology (CCB), Cancer Prevention and Control (CPC), Cancer Genetics and Epigenetics (CGE) and Discovery and Developmental Therapeutics (DDT). Each of these programs support collaborative research and allow leading cancer researchers to combine their varied skills across specialties.
WCI works within the research environment of Emory’s Woodruff Health Sciences Center, a national leader in life sciences. Focusing primarily on translational research, Emory uses its groundbreaking laboratory discoveries as a means to continually advance the quality of treatment and patient care. There are currently 22 clinical trials underway at Winship. These research studies test new treatments to improve the options and outlook of cancer patients. For example, an open phase I clinical trial under the direction of Ramalingam tests a new combination of chemotherapy treatments for advanced solid tumors applicable to cases of mesothelioma and a variety of other cancer types. Efforts such as this by specialists devoted to eliminating the burden of cancer make the Winship Cancer Institute a premier destination for cancer care.
Disclaimer: Winship Cancer Institute of Emory University has no professional affiliation with Asbestos.com.
Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.
View our resources for patients and familiesGet Help Today